Key Developments

In January 2023: Catalent announced a development and license agreement with Ethicann Pharmaceuticals Inc., a specialty pharmaceutical company based in Canada and the US. Ethicann focuses on high-value cannabinoid drug therapies and will leverage Catalent's Zydis orally disintegrating tablet (ODT) technology to advance its clinical drug pipeline. Under the agreement, Catalent will use its Zydis technology to create pharmaceutical products containing cannabidiol (CBD) and tetrahydrocannabinol (THC) for use in Ethicann’s clinical trials targeting various conditions.
In March 2023: Bioindustries, a leading name in Live Biotech Process Development and Production (LBP), announced the inauguration of its new facility in Boston, Massachusetts. This new facility will further enhance Biose's established success in LBP process development and manufacturing, reinforcing its presence and operations within the US market.
In July 2023: Recipharm has opened a new analytical laboratory in Bangalore, India, designed to expand its global testing capabilities. The 5,000-square-foot laboratory will enhance Recipharm's analytical services, including testing for nitrosamines, extractables, leachables, and elemental impurities. This facility will support the company's biotech and pharmaceutical clients in the research and development of oral solids, drug delivery systems, inhalation products, vaccines, and injectables, all while maintaining full cGMP compliance.
In June 2022: Glenmark Pharmaceuticals launched a pioneering fixed-dose combination (FDC) medication, Indacaterol + Mometasone, for patients with uncontrolled asthma in India. Marketed under the brand name Indamet, Glenmark is the first company in India to commercialize this innovative FDC. The combination features Indacaterol, a long-acting beta-agonist, and Mometasone Furoate, an inhaled corticosteroid, and has been approved by the Drug Controller General of India (DCGI).